After the votes from the midterm elections were counted Tuesday and the Democrats had gained a majority in the US House of Representatives while Republicans reinvigorated their hold on the Senate, it was clear that a hot topic on voters’ minds was the high cost of drugs in the United States; however, questions remain as to what the newly elected officials will be able to accomplish to reduce prices.
After the votes from the midterm elections were counted Tuesday and the Democrats had gained a majority in the US House of Representatives while Republicans reinvigorated their hold on the Senate, it was clear that a hot topic on voters’ minds was the high cost of drugs in the United States; however, questions remain as to what the newly elected officials will be able to accomplish to reduce prices.
Due to Congress being divided amongst the 2 parties, each group will struggle to move legislation without the other’s support. On Tuesday, House Minority Leader Nancy Pelosi, D-California, said that Democrats could work with President Trump to lower drug prices. “I think we could find common ground on reducing the cost of prescription drugs, if the president is serious about his saying that he wants to do that,” said Pelosi in an interview with PBS NewsHour.
Before the elections had taken place, the pharma industry saw potential gridlock in Congress as a positive that could benefit drug makers. However, as this is one issue that both sides of the aisle seem to agree on, Cowen Washington Research Group’s healthcare and pharma managing director Rick Weissenstein, noted that the election result could actually result in “a constant drumbeat of hearings and bad press,” as reported by FiercePharma. Because the House has subpoena powers, said Weissenstein, it could move to subpoena drug makers for research and development costs, launch investigations, and hold hearings, among other things.
Indeed, analysts are in agreement that the next 2 years could see a very healthcare-focused Congress. “With Democrats running key committees—including Elijah Cummings, D-Maryland, who has been focused on healthcare and who will now head the [Committee on Oversight and Government Reform]—we believe that drug prices and healthcare will stay a hot topic,” said Wells Fargo analyst David Maris, also reported by FiercePharma.
Also on the horizon is a potential push for the Medicare-for-all platform that many progressive Democrats ran on in the midterm elections. Yet to date, the Republican Trump administration has been looking to generate more transparency across the drug pricing process through efforts such as proposing to require drug makers to include a drug’s list price in direct-to-consumer advertising.
More recently, the administration has announced that it will be looking into using an International Pricing Index to more closely align its Medicare payment amount for selected Part B drugs with prices paid in other nations. CMS is taking comments on that proposal until December 31, 2018.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.